扶正解毒法配合新辅助化疗治疗乳腺癌33例临床研究

Added Health-restoring and Detoxin on New Chemotherapy to Treat 33 Cases of Breast Cancer

目的:探讨扶正解毒中药复方复康灵配合新辅助化疗治疗乳腺癌的临床意义。方法:将临床分期为Ⅱ～Ⅲ期乳腺癌患者分为治疗组和化疗后对照组,治疗组用复康灵+CTF方案化疗3个周期,对照组CTF方案化疗3个周期,疗程结束后观察近期疗效并采用免疫组织化学方法检测新辅助化疗前后肿瘤组织中P-gp及GST-π的表达,进行组间比较及相关性分析。结果:近期疗效:治疗组完全缓解率为12.1%,总缓解率为72.7%;对照组完全缓解率为0.0%,总缓解率为45%,2组间比较,差异有统计学意义(P<0.05);治疗组新辅助化疗前后P-gp和GST-π阳性率均增高,前者差异有统计学意义;治疗组化疗后P-gp阳性率为12.1%,对照组P-gp阳性率为40.0%,2组比较,P<0.05,差异有统计学意义;治疗组GST-π阳性率为36.4%,对照组GST-π阳性率为55.0%,2组比较,P>0.05。结论:乳腺癌新辅助化疗可使肿瘤缩小,降低临床分期,有助于手术治疗及术式的选择,而扶正解毒中药复方复康灵配合新辅助化疗治疗乳腺癌可以逆转多药耐药的部分基因表达,从而提高化疗疗效,减毒增效。

Objective：To investigate clinical effect of Fukangling（health-restoring and detoxin Chinese medical compound）in combination with a new chemotherapy on breast cancer.Methods：In a 3-cycle trial,patients in phase Ⅱ～Ⅲ were randomized to 2 regimen：Fukangling＋ CTF,CTF.At the end of study,efficacy as well as expression of P-gp and GST-πwere observed using immunohistochemistry methods.Results：treatment group：complete remission rate=12.1%,total remission rate=72.7% vs.control group：complete remission rate=0%,total remission rate=45%（P0.05）;After addition of new chemotherapy,P-gp and GST-πpositive rate raised（P0.05）;P-gp positive rates were 12.1% vs.40.0%（P0.05）;GST-πpositive rates were 36.4% vs.55.0%（P0.05）.Conclusion：The new chemotherapy can shrink tumor,lower clinical severity grade and facilitate operation.When Fukangling adds on to the chemo,partial gene expression was reversed to achieve higher efficacy and lower grade adverse reaction.